1. Li, PK, Szeto, CC, Piraino, B, et al. Ispd peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36: 481–508.
Google Scholar | SAGE Journals2. Piraino, B . Peritonitis as a complication of peritoneal dialysis. J Am Soc Nephrol 1998; 9: 1956–1964.
Google Scholar | Crossref | Medline3. Piraino, B, Bernardini, J, Brown, E, et al. Ispd position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31: 614–630.
Google Scholar | SAGE Journals4. De Vriese, AS, Vandecasteele, SJ. Vancomycin: the tale of the vanquisher and the pyrrhic victory. Perit Dial Int 2014; 34: 154–161.
Google Scholar | Medline5. Mulhern, JG, Braden, GL, O’Shea, MH, et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995; 25: 611–615.
Google Scholar | Crossref | Medline6. Stevenson, S, Tang, W, Cho, Y, et al. The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis. Perit Dial Int 2015; 35: 222–228.
Google Scholar | SAGE Journals7. Blunden, M, Zeitlin, D, Ashman, N, et al. Single UK centre experience on the treatment of PD peritonitis–antibiotic levels and outcomes. Nephrol Dial Transplant 2007; 22: 1714–1719.
Google Scholar | Crossref | Medline8. Vandecasteele, SJ, De Vriese, AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010; 77: 760–764.
Google Scholar | Crossref | Medline9. Blowey, DL, Warady, BA, Abdel-Rahman, S, et al. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis. Perit Dial Int 2007; 27: 79–85.
Google Scholar | SAGE Journals10. Fish, R, Nipah, R, Jones, C, et al. Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels. Perit Dial Int 2012; 32: 332–338.
Google Scholar | SAGE Journals11. Cho, Y, Badve, SV, Hawley, CM, et al. Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study. Perit Dial Int 2013; 33: 75–85.
Google Scholar | SAGE Journals12. Xu, R, Yang, Z, Qu, Z, et al. Intraperitoneal vancomycin plus either oral moxifloxacin or intraperitoneal ceftazidime for the treatment of peritoneal dialysis-related peritonitis: a randomized controlled pilot study. Am J Kidney Dis 2017; 70: 30–37.
Google Scholar | Crossref | Medline13. Ye, H, Lin, X, Qiu, Y, et al. Higher alkaline phosphatase was associated with the short-term adverse outcomes of peritoneal dialysis-related peritonitis. Clin Chem Lab Med 2015; 53: e113–6.
Google Scholar | Crossref | Medline14. Zalunardo, NY, Rose, CL, Ma, IW, et al. Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis. Kidney Int 2007; 71: 687–692.
Google Scholar | Crossref | Medline15. Johnson, DW . Do antibiotic levels need to be followed in treating peritoneal dialysis-associated peritonitis? Semin Dial 2011; 24: 445–456.
Google Scholar | Crossref | Medline16. Wiggins, KJ, Johnson, DW, Craig, JC, et al. Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 2007; 50: 967–988.
Google Scholar | Crossref | Medline17. Montanes Pauls, B, Alminana, MA, Casabo Alos, VG. Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis. Eur J Pharm Sci 2011; 43: 212–216.
Google Scholar | Crossref | Medline